The Medical Letter. on Drugs and Therapeutics
|
|
- Madison Johnson
- 6 years ago
- Views:
Transcription
1 The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: Last updated: April 27, 2017 Comparison Table: Some Topical Corticosteroids The Medical Letter on Drugs and Therapeutics Comparison Table: Some Topical Corticosteroids 1,2 Super-High Potency Betamethasone dipropionate augmented generic Apply once/d or bid Should only be used short-term $ (15 g x 2) Diprolene (Merck) Clobetasol propionate generic Clobex (Galderma) gel foam spray shampoo Apply once/d Should not be used under occlusion Ointments are generally the most effective formulations Foams and sprays can be applied to large areas, but the alcohol base used in many of them may cause burning Foam: dispense small amount onto a saucer or other cool surface; will melt immediately if dispensed onto hands (15 g x 2) (30 g) (30 g) (30 g) (50 ml) (60 ml) (50 g) (59 ml) (118 ml) (60 ml) spray (59 ml) shampoo Apply once/d (118mL) Olux (Prestium/Mylan) foam (50 g) Olux-E (Mylan) foam (50 g) Temovate (Fougera) (30 g) (30 g) Cormax (Hi Tech) (50 ml) Fluocinonide generic 0.1% Apply once/d (30 g) Vanos (Valeant) (30 g) Halobetasol propionate generic Apply once/d or bid (50 g) (50 g) Ultravate (Ranbaxy) (50 g) (50 g) (60 ml) e91
2 High Potency Amcinonide generic 0.1% or tid Should only be used short-term Betamethasone dipropionate augmented Apply once/d or bid generic $ (60 g) (15 g x 2) Diprolene AF (Merck) Betamethasone dipropionate generic Desoximetasone generic Topicort (Taro) 0.25% Apply once/d or bid (15 g x 2) (45 g) (60 g) (60 g) (60 g) (60 g) Desoximetasone generic gel (15 g x 2) Diflorasone diacetate generic Apply 1-3 times/d (30 g) Fluocinonide generic Apply 2-4 times/d (30 g) gel (30 g) (30 g) (60 ml) Halcinonide Halog (Ranbaxy) 0.1% -tid (30 g) (30 g) Mometasone furoate generic 0.1% Apply once/d (15 g x 2) Elocon (MSD) (15 g x 2) Medium-High Potency Amcinonide generic 0.1% or tid (30 g) Betamethasone dipropionate generic Betamethasone valerate generic Desoximetasone generic 0.1% Apply once/d or bid Apply 1-3 times/d (60 ml) (15 g x 2) (15 g x 2) (15 g x 2) (15 g x 2) Diflorasone diacetate generic Apply 1-3 times/d (30 g) Fluocinonide emollient generic Apply 2-4 times/d (30 g) Fluticasone propionate generic 0.005% (30 g) Triamcinolone acetonide generic 0.5% Apply 2-4 times/d (15 g x 2) or tid (15 g x 2) e92
3 Medium Potency Betamethasone dipropionate spray Sernivo: shake well before use Sernivo (Promius) Luxiq: dispense small amount onto a saucer or other cool surface; foam $ (120 ml) Betamethasone valerate generic 0.12% foam will melt immediately if dispensed onto hands (50 g) Luxiq (Prestium/Mylan) (50 g) Fluocinolone acetonide generic 0.025% Apply 3-4 times/d (15 g x 2) Synalar (Medimetriks) Apply 2-4 times/d (120 g) Flurandrenolide generic or tid (60 g) Cordran (Aqua) (60 g) Hydrocortisone valerate generic 0.2% or tid (15 g x 2 ) Mometasone furoate generic 0.1% Apply once/d (15 g x 2) Elocon (MSD) (15 g x 2) Triamcinolone acetonide generic 0.1% or tid 6.00 (30 g) 6.20 (30 g) Triderm (Crown) (30 g) Triamcinolone acetonide Trianex (Promius) Apply 2-4 times/d (430 g) Medium-Low Potency Betamethasone dipropionate generic (60 ml) Betamethasone valerate generic 0.1% Apply 1-3 times/d (15 g x 2) Desonide generic Apply 2-4 times/d (15 g x 2) Fluocinolone acetonide generic 0.025% Apply 2-4 times/d (15 g x 2) Synalar (Medimetriks) (120 g) Flurandrenolide generic or tid (120 g) (120 ml) Cordran (Aqua) (120 g) (120 ml) Fluticasone propionate generic Apply once/d or bid (30 g) Apply once/d (120 ml) Cutivate (PharmaDerm) Apply once/d or bid (30 g) Apply once/d (120 ml) e93
4 Medium-Low Potency (continued) Hydrocortisone butyrate generic 0.1% or tid $ (15 g x 2) (15 g x 2) (60 ml) Locoid (Onset) (15 g x 2) (15 g x 2) (60 ml) Locoid Lipo (15 g x 2) Hydrocortisone probutate Pandel (Sandoz) 0.1% Apply once/d or bid (80 g) Hydrocortisone valerate generic 0.2% or tid (15 g x 2) Prednicarbate generic 0.1% (60 g) (60 g) Dermatop (Valeant) (60 g) (60 g) Triamcinolone acetonide generic 0.025% Apply 2-4 times/d (15 g x 2) Triamcinolone acetonide generic 0.1% Apply 3-4 times/d (60 ml) Low Potency Alclometasone dipropionate generic -tid (60 g) (60 g) Betamethasone valerate generic 0.1% Verdeso should be dispensed by inverting can; upright actuation may cause incorrect dosage delivery (60 ml) Clocortolone pivalate generic 0.1% Apply tid (45 g) Cloderm (Promius) (45 g) Desonide generic (30 g) (60 ml) Desowen (Galderma) (60 g) (60 ml) Desonate (Bayer) gel (60 g) Verdeso (Stiefel) foam (100 g) Fluocinolone acetonide generic 0.01% Apply 2-4 times/d (60 g) (60 ml) Triamcinolone acetonide generic 0.025% Apply 2-4 times/d 7.20 (30 g) (60 ml) e94
5 Lowest Potency Hydrocortisone generic Hydrocortisone generic 2.5% 1.0% -qid Apply up to tid-qid Hydrocortisone 2.5% is available by prescription only Hydrocortisone 1% and 0.5% are available without a prescription Individual retailers may have their own OTC generic products May be ineffective for some indications $2.70 (20 g) 3.00 (30 g) (60 ml) 6.80 (30 g) 4 Safe for use on the face and intertriginous areas 6.80 (30 g) 4 Aquanil-HC (Person & Covey) 8.00 (120 ml) 4 Hydrocortisone generic 0.5% Apply up to tid-qid 3.30 (30 g) 5.00 (30 g) 4 Nu-Derm Tolereen (Obagi) 0.5% (57 g) 1. Drugs for psoriasis. Med Lett Drugs Ther 2015; 57: Drugs for allergic disorders. Med Lett Drugs Ther 2017; 59: Approximate WAC for smallest available package size. WAC = wholesaler acquisition cost or manufacturer s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource Monthly. April 5, Reprinted with permission by First Databank, Inc. All rights reserved Price according to walgreens.com. Accessed April 27, 2017.
Comparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationQuarterly pharmacy formulary change notice
Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics
More informationPharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationDrug Class Literature Scan: Topical Steroids
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationEffective for all members on August 1, 2017
August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List
More informationMichigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end
More informationDupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationDEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationThe Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationConnecticut Medicaid P&T Meeting Minutes December 2, 2010
Connecticut Medicaid P&T Meeting Minutes December 2, 2010 The meeting started at 6:34 pm Attendance Present Members: Carl Sherter, MD Peggy Manning Memoli, Pharm D Eric Einstein, MD Charles Thompson, MD
More informationBLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) report Title and TA publication number of static topic: Final decision:
More information2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014
2015 Medicare Step Therapy Criteria Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...
More informationTopical Immunomodulators
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Topical Immunomodulators Clinical Edit Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03%
More informationClinical pharmacology review for primary health care providers: II. Steroids
TCP 2015;23(1):15-20 http://dx.doi.org/10.12793/tcp.2015.23.1.15 Clinical pharmacology review for primary health care providers: II. Steroids TUTORIAL Seunghoon Han* Department of Clinical Pharmacology
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More information2014 Medicare Step Therapy Criteria. Last Modified: Last Submitted to CMS:
2014 Medicare Step Therapy Criteria Last Modified: 09.30.2014 Last Submitted to CMS: 09.02.2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...
More information84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents
Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents COMPOUND PRESCRIPTION 00000999119 00000999112 COMPOUND - RETINOIC ACID (TRETINOIN) () MISCELLANEOUS COMPOUND To be used when the compound
More informationALLERGIC RHINITIS-NASAL
ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step
More informationHigh-Cost Drug Exclusions
Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationLiterature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationStep Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
More informationManaging and Minimizing Flare-ups in Atopic Dermatitis
Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology
More informationTopical Products with Quantity Limits
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Page: 1 of 8 Last Review Date: November 30, 2018 Description Apexicon E Topical Cream 0.05% (diflorasone
More informationHigh-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
More informationCalgary Zone LTC Formulary Autosubstitution List
Calgary Zone LTC Formulary Autosubstitution List PURPOSE ASL-01 In order to simplify drug therapy, orders for one medication may be automatically substituted using a different, but therapeutically equivalent
More informationCalgary Zone LTC Formulary Autosubstitution List
Calgary Zone LTC Formulary Autosubstitution List PURPOSE ASL-01 In order to simplify drug therapy, orders for one medication may be automatically substituted using a different, but therapeutically equivalent
More informationDECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013
DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013 I. UNIFORM FORMULARY DRUG CLASS REVIEWS A. Corticosteroid Immune Modulators (Topical Steroids) Background
More information15 minute eczema consultation
THERAPY WORKSHOP 15 minute eczema consultation History Current treatments Examination Treatment Plan Written action plan Soap substitute/bath oil Antiseptic baths Emollients Topical steroids Other treatments
More informationBB&T 2014 Step Therapy Program Drug List
BB&T 2014 Step Therapy Program Drug List For the drug classifications listed in the table below, members must have tried one Step One medication within the past 130 days before a Step Two medication will
More information79 C. Michael Davenport Blvd. Suite A Frankfort, KY August 5, Dear Kentucky Medicaid Provider:
79 C. Michael Davenport Blvd. Suite A Frankfort, KY 40601 August 5, 2010 Dear Kentucky Medicaid Provider: Please be advised that the Department for Medicaid Services is making changes to the Kentucky Medicaid
More informationStep Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)
CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018
More informationMedication Quick Reference
Medication Quick Reference Topical steroids CLASS 1 SUPERPOTENT Betamethasone dipropionate Diprolene O/G 0.05% 15, 50 g Clobetasol propionate Temovate O/Cr 0.05% 15, 30, 45 g Temovate S 0.05% 25, 50 ml
More informationNHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)*
NHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)* The following interchanges have been implemented to ensure rational use of select drugs, to decrease drug expenditures, and to allow
More informationSelect Drug Quantity Management
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCategory Second-Line (Targeted) First-Line (Alternative) Most Common Indication
Step therapy requires trial of a step-one drug before a step-two drug will be covered under the plan. If your medical condition warrants, share this list with your doctor and ask her or him to prescribe
More information2019 PacificSource Health Plans Step Therapy Criteria. Last Modified: 02/22/2019 (All criteria reviewed at least once per year)
2019 PacificSource Health Plans Step Therapy Criteria Last Modified: 02/22/2019 (All criteria reviewed at least once per year) Table of Contents ACTICLATE... 3 AMITIZA/LINZESS... 4 ANTIDIABETICS Farxiga,
More informationLABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17
More informationDrug Allergy: A Rash ionale for Treatment
Drug Allergy: A Rash ionale for Treatment Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Jordan O. Powell, PharmD Clinical Pharmacist
More informationTopical Corticosteroids
Topical Corticosteroids Topical Cοrt cοsterοids Editors Howard L Maibach, San Francisco, Calif. Christian Surber, Basel 83 figures and 91 tables, 1992 KARG E R. Basel München Paris London NewYork New
More information2017 Step Therapy (ST) Criteria
2017 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationRelative Efficacy and Interchangeability of Various Clobetasol Propionate Vehicles in the Management of Steroid-Responsive Dermatoses
VLUM 66, NUMBR 3, MAY/JUN 25 Review Article Relative fficacy and Interchangeability of Various Clobetasol Propionate Vehicles in the Management of Steroid-Responsive Dermatoses Steven R. Feldman, MD, PhD
More informationNEW PRODUCTS: HAILEY TM 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets), 1 mg/20
DECEMBER 2018 U.S. PRODUCT CATALOG NEW PRODUCTS: HAILEY TM 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets), 1 mg/20 ESTRADIOL VAGINAL INSERTS USP, 10 MCG CLOBETASOL
More informationSkin Manifestations of Allergy
Dermatologic Manifestations of Allergy William Reisacher MD FACS FAAOA Assistant Professor Weill Cornell Medical College Skin Manifestations of Allergy Atopic dermatitis (atopic eczema, eczema) Contact
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 10/28/2014 Effective date: 11/15/2014 Therapeutic Classes reviewed: Pulmonary arterial hypertension
More informationUsing Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice)
Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice) Patient Case Study in Psoriasis Patient Case Study in Psoriasis William Smith,
More informationPHARMA-MEDIC SERVICES INC. POLICY MANUAL
PHARMA-MEDIC SERVICES INC. POLICY MANUAL SUBJECT: INDEX: P.5.a.iii Automatic-Therapeutic Substitution DATE: June 1/2011 REVISED: March 2, 2015., Feb 2017. PROCEDURE: 1. Long term care homes use the Manitoba
More informationDrug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of drugs by drug class
More informationADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 7/1/2017, Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of
More informationATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP
ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP Disclosures There are no financial relationships with commercial interests to disclose Ay unlabeled/unapproved
More informationBlueLink TPA FlexRx Updates
BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%
More informationCHANGES TO YOUR DRUG LIST
CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money At Cigna, it s our goal to offer you access to coverage for safe, effective and affordable medications.
More informationBelow is a summary of the PDL changes that will be effective May 1, All other agents in these classes will retain their current PDL listing.
STATE OF TENNESSEE DIVISION OF TENNCARE 310 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise you of information regarding the TennCare Pharmacy Program. Please forward or copy the
More informationThe Medical Letter. on Drugs and Therapeutics. Usual Adult Hypnotic Dose 1,2 Some Adverse Effects Comments Cost 3
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationDesigning a Campaign On Topical steroids misuse
Ministry Of Higher Education And Scientific Research University Of Al-Qadysiah College Of Pharmacy Designing a Campaign On Topical steroids misuse By: Hussein A. Abdulwahab Ali H. Abd Zaid Supervised By:
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Frequency of application of topical corticosteroids for atopic eczema
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE Frequency of application of topical corticosteroids for atopic eczema 1 Guidance This appraisal relates to the frequency of application of topical corticosteroids
More informationDRUG SCHEDULES REGULATION CHANGES JUNE 2018
DRUG SCHEDULES REGULATION CHANGES JUNE 2018 The following amendments to the Schedules to the Drug Schedules Regulation made under the Pharmacy Operations and Drug Scheduling Act came into effect on June
More information(12) Patent Application Publication (10) Pub. No.: US 2012/ A1
(19) United States US 2012O129824A1 (12) Patent Application Publication (10) Pub. No.: US 2012/0129824 A1 Angel et al. (43) Pub. Date: (54) PHARMACEUTICAL FORMULATIONS Publication Classification CONTAINING
More informationInternational Journal of Scientific & Engineering Research Volume 9, Issue 8, August ISSN
International Journal of Scientific & Engineering Research Volume 9, Issue 8, August-2018 881 Safety and efficiency of a topical corticosteroid in psoriasis Bahni Mohammed Ali Asiri Abstract: The aim of
More informationNew Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003
New Medicine Report Document Status Pimecrolimus Reviewed by Suffolk D&T RED- Hospital only Date of Last Revision 6 th March 2003 Approved Name Pimecrolimus Trade Name Elidel Manufacturer Novartis Legal
More informationProduct List Finished Dosage Forms (FDF) B2B Business
Product List 2017 Finished Dosage Forms (FDF) B2B Business Anaesthetics Dermatology Lidocaine Lidocaine and Prilocaine Dexmedetomidine Hydrochloride Anti-Infectives Amoxicillin Trihydrate and Potassium
More informationPRODUCT MONOGRAPH. Taro-Mometasone Cream (Mometasone Furoate Cream, USP) 0.1% (w/w)
PRODUCT MONOGRAPH Pr Taro-Mometasone Cream (Mometasone Furoate Cream, USP) 0.1% (w/w) Pr Taro-Mometasone Ointment (Mometasone Furoate Ointment, USP) 0.1% (w/w) Pr Taro-Mometasone Lotion (Mometasone Furoate
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE February 18, 2015 SUBJECT EFFECTIVE DATE January 21, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 21, 2015 Pharmacy Services Vincent D. Gordon, Deputy
More information2018 PacificSource Health Plans Step Therapy Criteria. Last Modified: 5/22/2018 (All criteria reviewed at least once per year)
2018 PacificSource Health Plans Step Therapy Criteria Last Modified: 5/22/2018 (All criteria reviewed at least once per year) Table of Contents ACE-I/ARB... 3 ACNE AGENTS Acanya, Azelex... 4 ACTICLATE...
More information(12) United States Patent
(12) United States Patent Nichols et al. USOO6830758B2 (10) Patent No.: () Date of Patent: Dec. 14, 2004 (54) PSORIASIS PATCH (75) Inventors: Jane Nichols, Bloomington, MN (US); Teri Buseman, Minnetonka,
More informationDUPIXENT (dupilumab) subcutaneous injection
DUPIXENT (dupilumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPrior Authorization Topical Immunomodulators Elidel and Protopic 0.03%
Drugs Requiring Label Name GCN ELIDEL 1% CREAM 15348 PROTOPIC 0.03% OINTMENT 12289 TACROLIMUS 0.03% OINTMENT 12289 Clinical Edit Criteria Logic 1. Does the client have a diagnosis of localized skin graft
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Review Proposal of NICE Technology Appraisal no. 81; on the frequency of application of topical Provisional matrix of consultees
More information3. Acyclovir 5% ointment with Dyclonine HCl 1% or Lidocaine 1% Compound Sig: Apply to affected area q2h (start applying prodromal stage)
Cincinnati Dental Association Great Cases with New Faces November 17, 2010 THERAPEUTIC REGIMENS FOR SELECTED ORAL MUCOSAL DISEASES John A. Svirsky, DDS, MEd Virginia Commonwealth University (804) 828-0547
More informationTopical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities
DOI: 10.1111/j.1468-3083.2012.04522.x JEADV REVIEW ARTICLE Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities E. Castela, E. Archier, S. Devaux, A. Gallini,
More informationPRODUCT MONOGRAPH ELOCOM. Mometasone Furoate Cream, BP, 0.1% Mometasone Furoate Ointment, Merck Standard, 0.1% Mometasone Furoate Lotion, 0.
PRODUCT MONOGRAPH ELOCOM Mometasone Furoate Cream, BP, 0.1% Mometasone Furoate Ointment, Merck Standard, 0.1% Mometasone Furoate Lotion, 0.1% Topical Corticosteroid Therapy Merck Canada Inc. 16750 route
More informationSymbiotica Speciality Ingredients Sdn. Bhd. Malaysia
Established since 2001 Text Manufacturing Facility in Kulim, Kedah First Regionally Owned Manufacturer of APIs in and ASEAN Core Activity Research Development & Manufacture of Active Pharmaceutical Ingredients
More informationThe active ingredient of any pharmaceutical
Close Encounters With the Environment Stratum Corneum Absorption Kinetics of 2 Potent Topical Corticosteroid Formulations: A Pilot Study Zoe Diana Draelos, MD Practice Points Fluocinonide concentration
More informationTopical Agents Available Strengths. Fml Limits 0.05% NF $ % QL % ST % - $ % ST; QL % QL $ % NF $67.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Psoriasis (PsO) P & T DATE 2/13/2018 THERAPEUTIC CLASS Dermatology REVIEW HISTORY 2/17,2/16, 11/15, 5/15, LOB AFFECTED MCL
More informationPatient reported outcomes in chronic skin diseases: ehealth applications for clinical practice van Cranenburgh, O.D.
UvA-DARE (Digital Academic Repository) Patient reported outcomes in chronic skin diseases: ehealth applications for clinical practice van Cranenburgh, O.D. Link to publication Citation for published version
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More information2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important
More information